Reversibility of cirrhosis in chronic hepatitis B. (Q44832676)

6 December 2017

Reversibility of cirrhosis in chronic hepatitis B. (English)

1 reference

6 December 2017

0 references

1 reference

1

1 reference

6 December 2017

2

1 reference

PubMed ID

15067631

6 December 2017

Seyed Mohammad Tavangar

series ordinal

6

1 reference

Siavosh Nasseri-Moghaddam

6 December 2017

Nasser Rakhshani

3

0 references

series ordinal

4

object named as

Siavosh Nasseri-Moghaddam

1 reference

6 December 2017

7

Amir Ali Sohrabpour

1 reference

6 December 2017

5

Shahin Merat

1 reference

PubMed ID

15067631

6 December 2017

language of work or name

English

0 references

publication date

1 April 2004

1 reference

Clinical Gastroenterology and Hepatology

6 December 2017

1 reference

6 December 2017

2

1 reference

6 December 2017

4

1 reference

6 December 2017

344-347

1 reference

Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies

6 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

Reversibility of hepatic fibrosis in autoimmune hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

Hepatic fibrosis. Pathogenesis and principles of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

Is liver fibrosis reversible?

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

Decreasing fibrogenesis: an immunohistochemical study of paired liver biopsies following lamivudine therapy for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

Histological outcome during long-term lamivudine therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

Resolution of cirrhosis in autoimmune hepatitis with corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

1 reference

7 January 2021

A controlled trial of interferon with or without prednisone priming for chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1016%2FS1542-3565%2804%2900066-7

7 January 2021

10.1016/S1542-3565(04)00066-7

Identifiers

DOI

1 reference

6 December 2017

1 reference

PubMed ID

15067631